Lesional magnetization transfer ratio: A feasible outcome for remyelinating treatment trials in multiple sclerosis

Ij Van Den Elskamp, D. L. Knol, H. Vrenken, G. Karas, A. Meijerman, M. Filippi, L. Kappos, F. Fazekas, K. Wagner, C. Pohl, R. Sandbrink, C. H. Polman, B. M J Uitdehaag, F. Barkhof

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Magnetization transfer ratio (MTR) is a sensitive parameter to quantify the integrity of myelinated white matter in patients with multiple sclerosis. Lesional MTR decreases in the acute phase due to demyelination, and subsequently shows recovery depending on the degree of remyelination in the absence of axonal loss. Recovery of average lesion MTR therefore might prove a viable outcome measure to assess the effect of remyelinating agents. Our objective was to determine the required sample size for phase II multicentre clinical trials using the recovery of average lesion MTR as primary outcome measure. With 7-monthly MRI scans, the MTR evolution of 349 new enhancing lesions before and after enhancement was assessed in 32 MS patients from 5 centres. Multilevel models were fitted to the data yielding estimates for the variance components, which were applied in power calculations. Sample sizes were determined for placebo-controlled, multicentre trials using lesional MTR recovery post-enhancement as primary outcome measure. Average lesion MTR decreased slightly in the build-up to enhancement, decreased dramatically during enhancement and showed recovery in the period after cessation. The power calculations showed that for a power of 80%, approximately 136 patients per trial (mean number of 6 lesions per patient) are required to detect a 30% increase in lesional MTR post-enhancement compared with placebo, whereas 48 subjects are required to detect a 50% increase in lesional MTR compared with placebo. Recovery of lesion MTR is a feasible outcome measure for future multicentre clinical trials measuring the effect of remyelinating agents.

Original languageEnglish
Pages (from-to)660-669
Number of pages10
JournalMultiple Sclerosis Journal
Volume16
Issue number6
DOIs
Publication statusPublished - 2010

Fingerprint

Multiple Sclerosis
Outcome Assessment (Health Care)
Multicenter Studies
Placebos
Sample Size
Phase II Clinical Trials
Demyelinating Diseases
Magnetic Resonance Imaging
Clinical Trials

Keywords

  • Magnetic resonance imaging
  • Magnetization transfer ratio
  • Multiple sclerosis
  • Sample size

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Lesional magnetization transfer ratio : A feasible outcome for remyelinating treatment trials in multiple sclerosis. / Van Den Elskamp, Ij; Knol, D. L.; Vrenken, H.; Karas, G.; Meijerman, A.; Filippi, M.; Kappos, L.; Fazekas, F.; Wagner, K.; Pohl, C.; Sandbrink, R.; Polman, C. H.; Uitdehaag, B. M J; Barkhof, F.

In: Multiple Sclerosis Journal, Vol. 16, No. 6, 2010, p. 660-669.

Research output: Contribution to journalArticle

Van Den Elskamp, I, Knol, DL, Vrenken, H, Karas, G, Meijerman, A, Filippi, M, Kappos, L, Fazekas, F, Wagner, K, Pohl, C, Sandbrink, R, Polman, CH, Uitdehaag, BMJ & Barkhof, F 2010, 'Lesional magnetization transfer ratio: A feasible outcome for remyelinating treatment trials in multiple sclerosis', Multiple Sclerosis Journal, vol. 16, no. 6, pp. 660-669. https://doi.org/10.1177/1352458510364630
Van Den Elskamp, Ij ; Knol, D. L. ; Vrenken, H. ; Karas, G. ; Meijerman, A. ; Filippi, M. ; Kappos, L. ; Fazekas, F. ; Wagner, K. ; Pohl, C. ; Sandbrink, R. ; Polman, C. H. ; Uitdehaag, B. M J ; Barkhof, F. / Lesional magnetization transfer ratio : A feasible outcome for remyelinating treatment trials in multiple sclerosis. In: Multiple Sclerosis Journal. 2010 ; Vol. 16, No. 6. pp. 660-669.
@article{c2dc6a13e0b84f95945cd43e04d6345a,
title = "Lesional magnetization transfer ratio: A feasible outcome for remyelinating treatment trials in multiple sclerosis",
abstract = "Magnetization transfer ratio (MTR) is a sensitive parameter to quantify the integrity of myelinated white matter in patients with multiple sclerosis. Lesional MTR decreases in the acute phase due to demyelination, and subsequently shows recovery depending on the degree of remyelination in the absence of axonal loss. Recovery of average lesion MTR therefore might prove a viable outcome measure to assess the effect of remyelinating agents. Our objective was to determine the required sample size for phase II multicentre clinical trials using the recovery of average lesion MTR as primary outcome measure. With 7-monthly MRI scans, the MTR evolution of 349 new enhancing lesions before and after enhancement was assessed in 32 MS patients from 5 centres. Multilevel models were fitted to the data yielding estimates for the variance components, which were applied in power calculations. Sample sizes were determined for placebo-controlled, multicentre trials using lesional MTR recovery post-enhancement as primary outcome measure. Average lesion MTR decreased slightly in the build-up to enhancement, decreased dramatically during enhancement and showed recovery in the period after cessation. The power calculations showed that for a power of 80{\%}, approximately 136 patients per trial (mean number of 6 lesions per patient) are required to detect a 30{\%} increase in lesional MTR post-enhancement compared with placebo, whereas 48 subjects are required to detect a 50{\%} increase in lesional MTR compared with placebo. Recovery of lesion MTR is a feasible outcome measure for future multicentre clinical trials measuring the effect of remyelinating agents.",
keywords = "Magnetic resonance imaging, Magnetization transfer ratio, Multiple sclerosis, Sample size",
author = "{Van Den Elskamp}, Ij and Knol, {D. L.} and H. Vrenken and G. Karas and A. Meijerman and M. Filippi and L. Kappos and F. Fazekas and K. Wagner and C. Pohl and R. Sandbrink and Polman, {C. H.} and Uitdehaag, {B. M J} and F. Barkhof",
year = "2010",
doi = "10.1177/1352458510364630",
language = "English",
volume = "16",
pages = "660--669",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Lesional magnetization transfer ratio

T2 - A feasible outcome for remyelinating treatment trials in multiple sclerosis

AU - Van Den Elskamp, Ij

AU - Knol, D. L.

AU - Vrenken, H.

AU - Karas, G.

AU - Meijerman, A.

AU - Filippi, M.

AU - Kappos, L.

AU - Fazekas, F.

AU - Wagner, K.

AU - Pohl, C.

AU - Sandbrink, R.

AU - Polman, C. H.

AU - Uitdehaag, B. M J

AU - Barkhof, F.

PY - 2010

Y1 - 2010

N2 - Magnetization transfer ratio (MTR) is a sensitive parameter to quantify the integrity of myelinated white matter in patients with multiple sclerosis. Lesional MTR decreases in the acute phase due to demyelination, and subsequently shows recovery depending on the degree of remyelination in the absence of axonal loss. Recovery of average lesion MTR therefore might prove a viable outcome measure to assess the effect of remyelinating agents. Our objective was to determine the required sample size for phase II multicentre clinical trials using the recovery of average lesion MTR as primary outcome measure. With 7-monthly MRI scans, the MTR evolution of 349 new enhancing lesions before and after enhancement was assessed in 32 MS patients from 5 centres. Multilevel models were fitted to the data yielding estimates for the variance components, which were applied in power calculations. Sample sizes were determined for placebo-controlled, multicentre trials using lesional MTR recovery post-enhancement as primary outcome measure. Average lesion MTR decreased slightly in the build-up to enhancement, decreased dramatically during enhancement and showed recovery in the period after cessation. The power calculations showed that for a power of 80%, approximately 136 patients per trial (mean number of 6 lesions per patient) are required to detect a 30% increase in lesional MTR post-enhancement compared with placebo, whereas 48 subjects are required to detect a 50% increase in lesional MTR compared with placebo. Recovery of lesion MTR is a feasible outcome measure for future multicentre clinical trials measuring the effect of remyelinating agents.

AB - Magnetization transfer ratio (MTR) is a sensitive parameter to quantify the integrity of myelinated white matter in patients with multiple sclerosis. Lesional MTR decreases in the acute phase due to demyelination, and subsequently shows recovery depending on the degree of remyelination in the absence of axonal loss. Recovery of average lesion MTR therefore might prove a viable outcome measure to assess the effect of remyelinating agents. Our objective was to determine the required sample size for phase II multicentre clinical trials using the recovery of average lesion MTR as primary outcome measure. With 7-monthly MRI scans, the MTR evolution of 349 new enhancing lesions before and after enhancement was assessed in 32 MS patients from 5 centres. Multilevel models were fitted to the data yielding estimates for the variance components, which were applied in power calculations. Sample sizes were determined for placebo-controlled, multicentre trials using lesional MTR recovery post-enhancement as primary outcome measure. Average lesion MTR decreased slightly in the build-up to enhancement, decreased dramatically during enhancement and showed recovery in the period after cessation. The power calculations showed that for a power of 80%, approximately 136 patients per trial (mean number of 6 lesions per patient) are required to detect a 30% increase in lesional MTR post-enhancement compared with placebo, whereas 48 subjects are required to detect a 50% increase in lesional MTR compared with placebo. Recovery of lesion MTR is a feasible outcome measure for future multicentre clinical trials measuring the effect of remyelinating agents.

KW - Magnetic resonance imaging

KW - Magnetization transfer ratio

KW - Multiple sclerosis

KW - Sample size

UR - http://www.scopus.com/inward/record.url?scp=77953789338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953789338&partnerID=8YFLogxK

U2 - 10.1177/1352458510364630

DO - 10.1177/1352458510364630

M3 - Article

C2 - 20350960

AN - SCOPUS:77953789338

VL - 16

SP - 660

EP - 669

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -